Gsk (GLAXF) Liabilities from Discontinued Operations (2022 - 2025)
Gsk (GLAXF) recorded quarterly Liabilities from Discontinued Operations of 184893101.59 in Q4 2025, up 99.18% quarter-over-quarter from 22478758539.5 in Q2 2022.
Gsk (GLAXF) Liabilities from Discontinued Operations (2022 - 2025) Analysis & Trends
Gsk's Liabilities from Discontinued Operations history runs 2 years deep, the most recent figure standing at 184893101.59 for Q4 2025.
- In Q4 2025, Liabilities from Discontinued Operations changed N/A year-over-year to 184893101.59; the TTM figure through Dec 2025 stood at 184893101.59 (changed N/A YoY), while the FY2025 annual figure was 183272936.69, changed N/A from the prior year.
- Liabilities from Discontinued Operations was 184893101.59 for Q4 2025 at Gsk, up from 22478758539.5 in the prior quarter.
- In the past five years, Liabilities from Discontinued Operations ranged from a high of 184893101.59 in Q4 2025 to a low of 22478758539.5 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn |
| 10 | Gsk | - | - | 7.76 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -184.89 Mn |
| Dec 31, 2025 | -184.89 Mn |
| Jun 30, 2022 | -22.48 Bn |
| Jun 30, 2022 | -22.48 Bn |